Targeting Envelope Proteins of Poxviruses to Repurpose Phytochemicals against Monkeypox: An In Silico Investigation

Gulati, Pallavi; Chadha, Jatin; Harjai, Kusum; Singh, Sandeepa

doi:10.20944/preprints202210.0302.v1

Cited by 3 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, no effective antiviral drugs are available to treat LSD. Nonetheless, FDA-approved drugs and phytocompounds that are effective against other poxviruses may be repurposed against the LSDV (Gulati et al, 2023). The disease can only be controlled in endemic areas via mass vaccinations, imposing movement restrictions (quarantine), and removing suspected or infected animals (Sevik and Dogan, 2017).…”

Section: Diagnosis Preventive Measures and Treatment Of Lsdmentioning

confidence: 99%

Lumpy Skin Disease: A Comprehensive Review on Virus Biology, Pathogenesis, and Sudden Global Emergence

Moudgil¹,

Chadha²,

Khullar³

et al. 2023

Preprint

View full text Add to dashboard Cite

The lumpy skin disease virus (LSDV) is an animal virus and a member of the Poxviridae family, which causes lumpy skin disease (LSD) in livestock animals like cows and buffaloes. LSD is an important transboundary disease of economic importance that was first discovered in 1929 in Zambia. LSDV has been prevalent in African countries, where several outbreaks have been reported previously. However, the virus has spread rapidly across the Middle East in the past two decades, reaching Russia and, recently, the Asian subcontinent. With the unprecedented cluster outbreaks reported across Asian countries, LSDV is certainly undergoing an epidemiological shift and expanding its geographical footprint globally. The recent LSD outbreaks have gained attention from global regulatory authorities and raised serious concerns among epidemiologists and veterinary researchers. Although there is no dearth of knowledge about LSDV, the disease lacks networked global surveillance and management, consequently making the current statistics deficient, fragmented, and unreliable. Hence, recurrent LSD outbreaks seriously threaten the global livestock industry. This review provides recent insights into LSDV by augmenting latest literature associated with its epidemiology, pathogenesis, transmission, currently-available intervention strategies, and economic implications on the dairy industries. The review also critically examines the changing epidemiological footprint of LSD and speculates on the possible reasons contributing to the ongoing multi-country LSD outbreak.

show abstract

Section: Diagnosis Preventive Measures and Treatment Of Lsdmentioning

confidence: 99%

Lumpy Skin Disease: A Comprehensive Review on Virus Biology, Pathogenesis, and Sudden Global Emergence

Moudgil¹,

Chadha²,

Khullar³

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…15,16 In the cytoplasm of infected cells, MPXV employs several virally encoded proteins, including cysteine proteinase, to replicate, as is the case with other poxviruses. 17 In the life cycle of most viruses, proteases catalyze the cleavage of viral precursor polyproteins, playing a pivotal part in the process. Therefore, cysteine proteinase and other proteases enzymes are promising targets for the development of new antiviral medicines.…”

Section: Introductionmentioning

confidence: 99%

Computational Purposing Phytochemicals against Cysteine Protease of Monkeypox Virus: An In-silico Approach

Bansal¹,

Gupta²,

Sangwan³

et al. 2022

J. Pure Appl. Microbiol.

View full text Add to dashboard Cite

The development and evolution of viruses that cause disease have presented a formidable challenge to contemporary medicine and the global economy, not to mention a catastrophic risk to human health. Almost all of these viruses are zoonotic, meaning they were first identified in animals and then spread to humans. An emerging virus may cause only a few isolated instances, resulting in a limited outbreak, or it may cause widespread infection and spread to other parts of the world, triggering a full-blown epidemic. These kinds of emerging occurrences have occurred frequently and in many different forms during the past few decades. Monkeypox is a zoonotic disease caused by the monkeypox virus, a member of the orthopox family that also includes variola, cowpox, and vaccinia. Both animals and humans can get infected by this virus. Similar to smallpox this disease shows less severe rashes and lower mortality rate. The outbreak of monkeypox was declared a global public health emergency by the World Health Organization in July 2022. Unknown mutations and variations are linked to the recent epidemic. Presently, FDA approved tecovirimat, cidofovir and brincidofovir are there in market to treat monkeypox virus. But there are some side effects of these drugs as they are synthetic. So, scientists are working on natural remedies that can be used as alternative to these drugs. In the present study virtual screening of phytochemicals (N-(2-Allylcarbamoyl-4-chloro-phenyl)-3,4-dimethoxy-benzamide, 6-Dimethylaminonaphthene-1-sulfonicacid amide, Oleic Acid and dipentyl ester) from Allophylus serratus were employed against core viral cysteine proteases from monkeypox virus was done. The docking study revealed that selected ligands bind with target viral protein with binding affinity in the range of -5.0 to -6.7 kcal/mol. N-(2-Allylcarbamoyl-4-chloro-phenyl)-3,4-dimethoxy-benzamide showed the highest binding affinity of -6.7 kcal/mol which can be investigated in the future to design potential drugs against monkeypox virus. Thus, this study foresees the possibility of bioactive phytochemicals functioning as template molecules for further experimental evaluation of their efficiency against monkeypox virus.

show abstract

Breaking Barriers: Current Advances and Future Directions in Mpox Therapy

Shah,

Modi

2024

CDT

View full text Add to dashboard Cite

Background: Mpox, a newly discovered zoonotic infection, can be transmitted from animal to human and between humans. Serological and genomic studies are used to identify the virus. Objective: Currently, there are no proven effective treatments for Mpox. Also, the safety and efficacy of intravenous vaccinia immune globulin, oral Tecovirimat (an inhibitor of intracellular viral release), and oral Brincidofovir (a DNA polymerase inhibitor) against the Mpox virus are uncertain, highlighting the need for more effective and safe treatments. As a result, drug repurposing has emerged as a promising strategy to identify previously licensed drugs that can be repurposed to treat Mpox. Results: Various approaches have been employed to identify previously approved drugs that can target specific Mpox virus proteins, including thymidylate kinase, D9 decapping enzyme, E8 protein, Topoisomerase1, p37, envelope proteins (D13, A26, and H3), F13 protein, virus's main cysteine proteases, and DNA polymerase. Conclusion: In this summary, we provide an overview of potential drugs that could be used to treat Mpox and discuss the underlying biological processes of their actions.

show abstract

Targeting Envelope Proteins of Poxviruses to Repurpose Phytochemicals against Monkeypox: An In Silico Investigation

Cited by 3 publications

References 41 publications

Lumpy Skin Disease: A Comprehensive Review on Virus Biology, Pathogenesis, and Sudden Global Emergence

Lumpy Skin Disease: A Comprehensive Review on Virus Biology, Pathogenesis, and Sudden Global Emergence

Computational Purposing Phytochemicals against Cysteine Protease of Monkeypox Virus: An In-silico Approach

Breaking Barriers: Current Advances and Future Directions in Mpox Therapy

Contact Info

Product

Resources

About